Mono Pharmacare Limited IPO: Issue Price, Listing Gain and Share Price Now
Mono Pharmacare Limited listed on 07-Sep-2023 at ₹30.45 against an issue price of ₹28 , a listing gain of +8.75%. It last traded at ₹8.4. This page is the record of that issue and what has happened to it since — reported figures only.
Mono Pharmacare Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹28 |
| Listing price (listing-day close) | ₹30.45 |
| Listing gain | +8.75% |
| Price now | ₹8.4 |
| Change from issue price | -70.00% |
| Change from listing-day close | -72.41% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Mono Pharmacare Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹28 |
| Issue size | ₹14.07 Cr |
| Fresh issue | ₹14.07 Cr |
| Issue opened | 28-Aug-2023 |
| Issue closed | 30-Aug-2023 |
| Listed on | 07-Sep-2023 |
| Exchange | NSE SME |
| Segment | SME |
| Lead managers | Unistone Capital (left lead) |
How the Mono Pharmacare Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 10.89x |
| NII | 8.00x |
| Retail | 19.40x |
| Total | 13.42x |
Mono Pharmacare Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹14.8 Cr |
| Trailing P/E | 42.40x |
| Return on capital employed | 4.5% |
| Return on equity | 1.1% |
| 52-week high | ₹25.5 |
| 52-week low | ₹7.5 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Mono Pharmacare Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.